JP5165688B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP5165688B2
JP5165688B2 JP2009535119A JP2009535119A JP5165688B2 JP 5165688 B2 JP5165688 B2 JP 5165688B2 JP 2009535119 A JP2009535119 A JP 2009535119A JP 2009535119 A JP2009535119 A JP 2009535119A JP 5165688 B2 JP5165688 B2 JP 5165688B2
Authority
JP
Japan
Prior art keywords
pyridin
propylsulfanyl
acetic acid
piperidyl
cyclohexylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009535119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508338A5 (show.php
JP2010508338A (ja
Inventor
マッコウル，ウィリアム
パッカー，マーティン
スコット，ジェームズ・スチュアート
ホウィッタモア，ポール・ロバート・オーウェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010508338A publication Critical patent/JP2010508338A/ja
Publication of JP2010508338A5 publication Critical patent/JP2010508338A5/ja
Application granted granted Critical
Publication of JP5165688B2 publication Critical patent/JP5165688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2009535119A 2006-11-03 2007-10-31 化合物 Active JP5165688B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86424706P 2006-11-03 2006-11-03
US86430306P 2006-11-03 2006-11-03
US60/864,247 2006-11-03
US60/864,303 2006-11-03
PCT/GB2007/004131 WO2008053194A2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors

Publications (3)

Publication Number Publication Date
JP2010508338A JP2010508338A (ja) 2010-03-18
JP2010508338A5 JP2010508338A5 (show.php) 2012-08-16
JP5165688B2 true JP5165688B2 (ja) 2013-03-21

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535119A Active JP5165688B2 (ja) 2006-11-03 2007-10-31 化合物

Country Status (30)

Country Link
US (3) US7964618B2 (show.php)
EP (2) EP2233480B1 (show.php)
JP (1) JP5165688B2 (show.php)
KR (1) KR101465275B1 (show.php)
CN (3) CN101787016B (show.php)
AR (1) AR063458A1 (show.php)
AT (1) ATE475649T1 (show.php)
AU (1) AU2007315955B2 (show.php)
BR (1) BRPI0717970C1 (show.php)
CA (1) CA2668006C (show.php)
CL (1) CL2007003176A1 (show.php)
CO (1) CO6321130A2 (show.php)
CY (1) CY1110813T1 (show.php)
DE (1) DE602007008137D1 (show.php)
DK (1) DK2086939T3 (show.php)
ES (2) ES2347491T3 (show.php)
HR (1) HRP20100522T1 (show.php)
IL (1) IL198231A0 (show.php)
MX (1) MX2009004707A (show.php)
NO (1) NO20091603L (show.php)
NZ (1) NZ576501A (show.php)
PE (1) PE20081487A1 (show.php)
PL (1) PL2086939T3 (show.php)
PT (1) PT2086939E (show.php)
RS (1) RS51451B (show.php)
RU (1) RU2451674C2 (show.php)
SI (1) SI2086939T1 (show.php)
TW (1) TW200827346A (show.php)
UY (1) UY30681A1 (show.php)
WO (1) WO2008053194A2 (show.php)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
MX2009012283A (es) 2007-05-18 2009-11-25 Shionogi & Co Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
WO2009098501A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
WO2009130496A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US20110092526A1 (en) * 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826
MX2012006028A (es) * 2009-11-24 2012-06-19 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013010382A1 (zh) * 2011-07-21 2013-01-24 山东亨利医药科技有限责任公司 杂环取代的嘧啶类化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
MA37764A1 (fr) 2012-06-20 2016-01-29 Hoffmann La Roche Composés n-alkyltriazole utilisés comme antagonistes de lpar
BR112014031108A2 (pt) 2012-06-20 2017-06-27 Hoffmann La Roche compostos de pirazol substituído como antagonistas de lpar
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (show.php) 1978-02-21 1981-03-27 Delalande Sa
US4734418A (en) 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
KR100532546B1 (ko) 1999-09-16 2005-12-01 다나베 세이야꾸 가부시키가이샤 방향족 질소 함유 6-원 고리 화합물
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003086410A1 (en) 2002-04-05 2003-10-23 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
BRPI0407810A (pt) 2003-02-26 2006-03-01 Banyu Pharma Co Ltd composto, composição farmacêutica, ativador da glicocinase, e, medicamento
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
US7659408B2 (en) 2003-08-07 2010-02-09 Merck Sharp & Dhome Corp. Pyrazole carboxamides as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
CA2549651A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US20080280868A1 (en) 2004-02-24 2008-11-13 Andrew John Eatherton Pyridine Derivatives and Their Use as Cb2 Receptor Modulators
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
EP1745019A1 (en) 2004-05-06 2007-01-24 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP4809339B2 (ja) 2004-06-28 2011-11-09 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン誘導体
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
JP2008519034A (ja) 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
CA2594098C (en) 2005-01-05 2014-04-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1928840B1 (en) 2005-04-05 2011-08-10 F. Hoffmann-La Roche AG 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006125958A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
EP1893609B1 (en) 2005-06-16 2009-11-18 Pfizer, Inc. N-(pyridin-2-yl)-sulfonamide derivatives
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
WO2007053657A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
AU2007210018A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
JP5031817B2 (ja) 2006-03-22 2012-09-26 エフ．ホフマン−ラ ロシュ アーゲー １１β−ＨＳＤ１としてのピラゾール
EP2010479A1 (en) 2006-04-07 2009-01-07 High Point Pharmaceuticals, LLC 11 beta-hydroxysteroid dehydrogenase type 1 active compounds
RU2008146591A (ru) 2006-04-27 2010-06-10 Зольвай Фармасьютиклз Гмбх (De) Применение модуляторов каннабиноидного рецептора свх в качестве модуляторов калиевых каналов
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
MX2009012283A (es) 2007-05-18 2009-11-25 Shionogi & Co Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
JP5189165B2 (ja) 2007-07-17 2013-04-24 エフ．ホフマン−ラ ロシュ アーゲー １１β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤
MX2010005048A (es) * 2007-11-06 2010-07-28 Astrazeneca Ab Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
WO2009098501A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
WO2009130496A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
US20110092526A1 (en) * 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826

Also Published As

Publication number Publication date
EP2086939B1 (en) 2010-07-28
NO20091603L (no) 2009-05-28
ES2347491T3 (es) 2010-10-29
CL2007003176A1 (es) 2008-07-25
SI2086939T1 (sl) 2010-10-29
RU2451674C2 (ru) 2012-05-27
BRPI0717970A2 (pt) 2013-11-05
US7964618B2 (en) 2011-06-21
ATE475649T1 (de) 2010-08-15
DK2086939T3 (da) 2010-10-11
WO2008053194A3 (en) 2008-10-02
CA2668006C (en) 2016-05-24
HRP20100522T1 (hr) 2010-11-30
US20080269288A1 (en) 2008-10-30
AU2007315955B2 (en) 2011-04-14
AR063458A1 (es) 2009-01-28
UY30681A1 (es) 2008-07-03
ES2423206T3 (es) 2013-09-18
TW200827346A (en) 2008-07-01
CA2668006A1 (en) 2008-05-08
WO2008053194A2 (en) 2008-05-08
AU2007315955A1 (en) 2008-05-08
CY1110813T1 (el) 2015-06-10
EP2086939A2 (en) 2009-08-12
JP2010508338A (ja) 2010-03-18
RU2009115830A (ru) 2010-12-10
US8673938B2 (en) 2014-03-18
RS51451B (sr) 2011-04-30
PE20081487A1 (es) 2009-01-11
US20090306075A1 (en) 2009-12-10
HK1135090A1 (en) 2010-05-28
BRPI0717970B8 (pt) 2020-12-01
EP2233480A1 (en) 2010-09-29
CN102603711A (zh) 2012-07-25
EP2086939B8 (en) 2011-06-22
BRPI0717970C1 (pt) 2021-05-25
PL2086939T3 (pl) 2011-09-30
KR20090075865A (ko) 2009-07-09
PT2086939E (pt) 2010-09-17
IL198231A0 (en) 2009-12-24
CN101787016A (zh) 2010-07-28
KR101465275B1 (ko) 2014-11-27
NZ576501A (en) 2011-03-31
CN101573336A (zh) 2009-11-04
CN101787016B (zh) 2013-08-28
BRPI0717970B1 (pt) 2019-10-22
DE602007008137D1 (en) 2010-09-09
US20090312372A1 (en) 2009-12-17
CN101573336B (zh) 2012-03-21
MX2009004707A (es) 2009-05-15
CO6321130A2 (es) 2011-09-20
EP2233480B1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
JP5165688B2 (ja) 化合物
CN103429585B (zh) 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物
US20090264401A1 (en) Substituted pyrimidin-5-carboxamides 281
BRPI0708264A2 (pt) piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
CZ3799A3 (cs) Indolový derivát k ošetřování osteoporézy
HK1135090B (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
SA07280596B1 (ar) مركبات بيريدين الأميد وأستخدامها كمثبطات إنزيم β-11 هيدروكسى ستيرويد ديهيدروجينيز من النوع الأول
HK1191938B (en) Indazolyl triazole derivatives as irak inhibitors
MXPA06008934A (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120628

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121219

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5165688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250